Table 3. Summary of validation work.
| Protein Id | Protein name |
LC-MS/MS |
Validation (western blots) |
Rodent western blots (P-value) | ||
|---|---|---|---|---|---|---|
| Direction | P-value | Direction | P-value | |||
| 1740 | DNM1 | − | 0.0006 | − | 0.039 | 0.731 |
| 787 | DTNA | − | 0.013 | − | 0.029 | 0.86 |
| 319 | NDUFV2 | + | 0.0037 | + | 5.6 × 10−6 | 0.55 |
| 282 | SEPT11 | + | 0.0004 | + | 2.46 × 10−7 | 0.715 |
| 347 | SSBP | − | 0.0006 | + | 0.019 | 0.703 |
| 2415 | GAD67 | − | 0.03 | − | 0.1 | 0.714 |
Abbreviations: LC-MS/MS, liquid chromatography–mass spectrometry; PSD, postsynaptic density.
Validation was undertaken using western blot analysis for DNM1, DTNA, NDUFV2, SEPT11 and SSBP1 in the PSD-enriched samples from the Stanley Foundation Array series. In keeping with our LC-MS/MS experiments, DNM1 and DTNA1 expression was reduced, and SEPT11 and NDUF2 were found to be increased. SSBP was found to be decreased in the MS data but increased by western blotting. This most probably is due to the antibody recognizing different/all isoforms of the protein. Western blot analyses demonstrated that DNM1, DTNA, NDUFV2, SEPT11 and SSBP1 were not significantly altered in rats treated with haloperidol.